0001544227-21-000011.txt : 20210302
0001544227-21-000011.hdr.sgml : 20210302
20210302171930
ACCESSION NUMBER: 0001544227-21-000011
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210226
FILED AS OF DATE: 20210302
DATE AS OF CHANGE: 20210302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Minai-Azary Jennifer Lynn
CENTRAL INDEX KEY: 0001844398
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35890
FILM NUMBER: 21705200
MAIL ADDRESS:
STREET 1: 110 MILLER AVENUE
STREET 2: SUITE 100
CITY: ANN ARBOR
STATE: MI
ZIP: 48104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Millendo Therapeutics, Inc.
CENTRAL INDEX KEY: 0001544227
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 451472564
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 110 MILLER AVENUE, SUITE 100
CITY: ANN ARBOR
STATE: MI
ZIP: 48104
BUSINESS PHONE: 734-845-9000
MAIL ADDRESS:
STREET 1: 110 MILLER AVENUE, SUITE 100
CITY: ANN ARBOR
STATE: MI
ZIP: 48104
FORMER COMPANY:
FORMER CONFORMED NAME: OvaScience, Inc.
DATE OF NAME CHANGE: 20120308
4
1
wf-form4_161472352776309.xml
FORM 4
X0306
4
2021-02-26
0
0001544227
Millendo Therapeutics, Inc.
MLND
0001844398
Minai-Azary Jennifer Lynn
C/O MILLENDO THERAPEUTICS, INC.
110 MILLER AVENUE, SUITE 100
ANN ARBOR
MI
48104
0
1
0
0
Chief Financial Officer
Stock Option (right to buy)
2.06
2021-02-26
4
A
0
110000
0
A
2031-02-25
Common Stock
110000.0
110000
D
1. Twenty-five percent (25%) of the shares subject to this option shall vest on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. However, all such options, to the extent outstanding immediately prior to a Change in Control (as defined in the 2019 Equity Incentive Plan), will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to such Change in Control.
/s/ Jennifer L. Minai-Azary
2021-03-02